Navigation Links
Inovio Pharmaceuticals Reports 2011 Second Quarter Financial Results
Date:8/8/2011

prime-boost vaccination strategy against genotype 1 hepatitis C virus (HCV) in a Phase I clinical study. Inovio will contribute its electroporation delivery technology to this collaboration. Clinical study costs will be shared equally by the collaborators.

Subsequent to the quarter, Inovio announced it had expanded its existing license agreement with the University of Pennsylvania, adding exclusive worldwide licenses for technology and intellectual property for novel DNA vaccines against prostate cancer, CMV (cytomegalovirus), malaria, hepatitis B, RSV (respiratory syncytial virus), and MRSA (methicillin-resistant staphylococcus aureus). The amendment also encompasses a new optimized IL-12 cytokine gene adjuvant.

Clinical DevelopmentInovio reported that 91% of evaluated patients (10 of 11) that had received three vaccinations of VGX-3100, its therapeutic SynCon® cervical dysplasia/cancer DNA vaccine delivered using intramuscular electroporation, displayed strong and persistent memory T-cell responses at month nine (six months after the last vaccination). Inovio subsequently reported long-term durability of T cell immune responses of up to two years (at the latest time measured) in 7 of 8 evaluated patients following a fourth vaccination of VGX-3100. This data further highlights the viability of using multiple booster vaccinations with a DNA vaccine delivered using electroporation, in contrast to other non-replicating vaccine vectors that may induce unwanted immune responses against the vector after multiple vaccinations.

Inovio is continuing to set up sites and enroll patients for its

SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Inovio Pharmaceuticals Demonstrates Positive Immune Responses in Phase I Clinical Trial of SynCon™ H5N1 Influenza Vaccine and Launches Multi-Subtype Influenza Vaccine Phase I
2. Inovio Pharmaceuticals Announces Transition of Avtar Dhillon to Non-Executive Chairman of the Board
3. Inovio Pharmaceuticals to Present at Scientific & Industry Conferences
4. Inovio Pharmaceuticals Subsidiary, VGX Animal Health, to Present at VetHealth Global 2011, June 14-17, 2011
5. Inovio Pharmaceuticals to Present at American Society of Gene & Cell Therapy Annual Meeting May 18 - 21, 2011
6. Inovio Pharmaceuticals Market-Leading Intellectual Property Recognized by MDB Capital Award
7. Inovio Pharmaceuticals to Present at Investor Conferences
8. Inovio Pharmaceuticals, Transgene and ChronTech Pharma to Collaborate on Heterologous Prime-Boost Therapeutic Vaccination Against Hepatitis C
9. OncoSec Medical Closes Purchase and License Agreement for Tumor Therapy Technology with Inovio Pharmaceuticals
10. Inovio Pharmaceuticals to Present at Scientific Conferences
11. Inovio Pharmaceuticals Receives U.S. DOD Small Business Innovation Research Grant for Multi-Vaccine DNA Delivery Device Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... , February 27, 2015 ... bahnbrechendes Überwachungssystem für kongestive Herzinsuffizienz (CHF) in ...     ... ein neuartiges Herzüberwachungssystem für Patienten mit kongestiver ... dass sie ein Finanzierungsvorhaben über 5 Mio. ...
(Date:2/27/2015)... JERUSALEM , Feb. 27, 2015  Chiasma, Inc., ... lead product for the orphan condition acromegaly, today announced ... round. Participants in the financing included new investors Rock ... chip public investment fund, as well as existing investors ... and ARCH Venture Partners. Chiasma intends ...
(Date:2/26/2015)... February 27, 2015 RnRMarketResearch.com ... market research report to its store. This report ... therapeutic pipeline. The report "Corneal Ulcers - Pipeline ... therapeutic development for Corneal Ulcers. Corneal Ulcers are ... bacterial infections, viral infections & fungal infections. The ...
Breaking Medicine Technology:Vectorious Medical Technologies schließt Finanzierungsvorhaben über 5 Mio. USD ab 2Chiasma Announces Completion of $70 Million Series E Financing 2Chiasma Announces Completion of $70 Million Series E Financing 3Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 2Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 3Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 4Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 5
... Heart, Inc. today announced that NewYork-Presbyterian Hospital/ Columbia ... U.S. center, and first in the Northeast, to ... of the DuraHeart Bridge-To-Transplant U.S. pivotal trial, a ... up to 40 centers nationwide. The trial ...
... 7 NovaBay Pharmaceuticals, Inc. (NYSE Alternext: ... novel, synthetic anti-infective products for the treatment ... bacterial, fungal, and viral infections without developing ... that NVC-422, the Company,s lead Aganocide(R) compound, ...
Cached Medicine Technology:Terumo Heart, Inc. Reports Clinical Progress in the DuraHeart(TM) U.S. Pivotal Trial as NewYork-Presbyterian Hospital/Columbia University Medical Center Implants First Patient 2Terumo Heart, Inc. Reports Clinical Progress in the DuraHeart(TM) U.S. Pivotal Trial as NewYork-Presbyterian Hospital/Columbia University Medical Center Implants First Patient 3NovaBay Pharmaceuticals Announces Lead Anti-infective Product Candidate, NVC-422, Shown to be Effective in Treating Topical Fungal Infection 2NovaBay Pharmaceuticals Announces Lead Anti-infective Product Candidate, NVC-422, Shown to be Effective in Treating Topical Fungal Infection 3NovaBay Pharmaceuticals Announces Lead Anti-infective Product Candidate, NVC-422, Shown to be Effective in Treating Topical Fungal Infection 4
(Date:3/1/2015)... Ticket Down is a reputable source for authentic tickets ... Deadheads have been anxiously anticipating this blockbuster weekend ever since ... 50 years ago back in the 60s in Palo Alto, ... death of Jerry Garcia in 1995. This beloved group ... bluegrass, folk, space rock and country to become an unforgettable ...
(Date:3/1/2015)... Indiana Fiber Network, LLC (IFN), the ... Networking, LLC (NewWays) selected IFN as primary fiber ... is well positioned to scale future backbone transport ... in rural parts of Indiana,” said Scott Reed, ... IFN Enterprise Sales Manager, IFN provides NewWays fiber ...
(Date:3/1/2015)... 2015 “ The Barrel Mill ” was ... which takes a look at the latest and coolest technology ... of NewsWatch and a technology expert, conducted the review and ... to drinks. , According to Home Distillation of Alcohol, it's ... Well, there’s a pretty cool product that’ll help anyone achieve ...
(Date:3/1/2015)... 28, 2015 CrossFit Attollo is a CrossFit ... offering a special discount to new members. Now through ... a three month contract will receive their fourth month half ... cost members $440. The three month contract is only ... then the fourth month comes in at only $55. The ...
(Date:2/28/2015)... 2015 In recent years Medical Marijuana has ... physicians as a way for them to expand their patient ... as medicine. Since the FDA still lists Cannabis as a ... to licensed physicians that can help guide them when ... Malka in Santa Cruz, CA is a leader in ...
Breaking Medicine News(10 mins):Health News:Grateful Dead Tickets at Soldier Field in Chicago: Ticket Down Slashes Grateful Dead Ticket Prices in Chicago at Soldier Field for 4th of July Weekend Celebration 2Health News:NewWays Networking Selects Indiana Fiber Network, LLC as Fiber Transport Provider 2Health News:An Oak Infusion Spiral was Featured on NewsWatch Television on January 30, 2015 2Health News:CrossFit Gym in Vancouver WA Offers Spring Special 2Health News:Reputable Cannabis Doctor In Santa Cruz and Monterey Joins the Medical Cannabis Network 2
... the lungs in bar workers according to a new study//. ... of the American Medical Association, and comes from Scotland where ... banned on March 26, 2006. ,Researchers such ... in Dundee, Scotland took this opportunity to study 77 nonsmoking ...
... of colon cancer (carcinoma) cases has been discovered by ... which could be the possible target for treatment against ... were able to rescue zebra fish from the effects ... gene, by genetically disabling (undoing) a molecule called C-Terminal ...
... "Mediterranean" diet rich in olive oil, vegetables, fruits, legumes, ... Alzheimer's disease according to U.S. researchers. ,Lead researcher ... Columbia University Medical Center in New York said, "We ... Alzheimer's disease." ,Scarmeas added that this benefit ...
... Dr Mukesh Haikerwal, said today the Government must make ... to be truly effective in meeting the needs of ... were announced today by the Prime Minister, and the ... care. ,While the AMA is generally pleased ...
... for permission with European medicine regulators to begin selling its ... move in the US last month, and comes slightly earlier ... to be one of GSK's most promising pipeline drugs as ... Code the sales of the drug could cross 2 bln ...
... under go lumpectomy feel that the outcome is a ... look, a recent survey has revealed. , ,The ... 2006 conference in San Francisco was witness to the ... of unhappy lumpectomy patients would explore the possibility of ...
Cached Medicine News:Health News:Novel Techniques to Tackle Colon Cancer 2Health News:Mental Health Package Regrettably Undervalues the Role of the GP 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: